Re: [標的] 請益 4147中裕營收分析

看板Stock作者isco (踏著月光回家)時間7年前 (2018/07/25 22:04)推噓8(9推 1噓 7→)

留言17則, 11人參與討論串2/3 (看更多)

※ 引述《haug (廣海)》之銘言： : 1. 標的：4147 中裕 : 2. 分類：請益 : 3. 分析/正文： : 已有的法說與新聞資料。4月銷售夥伴訂2500瓶，4月營收約3000W，概估每瓶1W,法說會張 : 董說明：患者一個月要用9瓶，後來5月營收0,6月營收約700W,即6月賣了700瓶，可以推估 : 目前用藥人約150人。之後可以追營收，看是否如期成長。公司目標2020高峰期歐美用藥 : 人數1W-1.5W,保守估用1W算。年營收1W*9*1W*12=108億，純益預估30%,(國外新藥廠純益) : 得純益32.4億，股本25億，估2020年eps=32.4/25*10=12.96。 : 至於估股價就要看成長性了，高成長本益比越高。 : 4. 進退場機制：(非長期投資者，必須有停損機制) Back 今天TH 中有關中裕的新聞，看來是正面的。 YahooFINANCE Trogarzo(TM) Included in Most Recent Treatment Guidelines Issued by Internatio nal Antiviral Society GlobeNewswireJuly 25, 2018, 7:50 PM GMT+8 MONTREAL, July 25, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechn ologies) (TH.TO) is pleased to announce that Trogarzo™ (ibalizumab-uiyk) inje ction is now included in the most recent version of the treatment guidelines i ssued by the International Antiviral Society-USA Panel (“IAS”). The guidelin es were published in the latest edition of the Journal of the American Medical Association (“JAMA”).1 The new IAS guidelines state that “Ibalizumab, an anti-CD4 monoclonal antibod y that inhibits HIV cell entry via CD4 binding, is active against CCR5- and C- X-C chemokine receptor 4 (CXCR4)–tropic HIV isolates and may be useful as a f ully active agent for patients with multiclass-resistant virus (evidence ratin g BII). Almost 50% of adults with virologic failure from multidrug-resistant H IV achieved undetectable HIV RNA levels at 24 weeks after receipt of biweekly intravenous ibalizumab (800 mg) with at least 1 other active drug.” “The inclusion of Trogarzo™ in those guidelines represents an important reco gnition of the usefulness and efficacy of Trogarzo™ from key opinion leaders in the field of HIV. This is yet more evidence that Trogarzo™ is well receive d by physicians and could help patients in need,” said Luc Tanguay, President and CEO, Theratechnologies Inc. About TrogarzoTMꀨibalizumab-uiyk) injection TROGARZO is a CD4-directed post-attachment HIV-1 inhibitor. Trogarzo™, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. Important Safety Information Before you receive Trogarzo™, tell your healthcare provider if you: are pregnant or plan to become pregnant.ꀠIt is not known if Trogarzo™ may ha rm your unborn baby. are breastfeeding or plan to breastfeed.ꀠIt is not known if Trogarzo™ passes into breast milk.ꀊ Tell your healthcare provider about all the medicines you take, including all prescription and over-the-counter medicines, vitamins, and herbal supplements. Trogarzo™ can cause serious side effects, including: Changes in your immune system (Immune Reconstitution Inflammatory Syndrome) ca n happen when you start taking HIV-1 medicines.ꀠYour immune system might get stronger and begin to fight infections that have been hidden in your body for a long time.ꀠTell your health care provider right away if you start having ne w symptoms after starting your HIV-1 medicine. The most common side effects of Trogarzo™ include: diarrhea, dizziness, nause a and rash. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Trogarzo ™. For more information, ask your healthcare provider or pharmacist. Full prescribing information available at www.trogarzo.com About Theratechnologies Theratechnologies (TH.TO) is a specialty pharmaceutical company addressing unm et medical needs to promote healthy living and an improved quality of life amo ng HIV patients. Further information about Theratechnologies is available on t he Company's website at烀ww.theratech.com乸nd on SEDAR at烀ww.sedar.com. Forward-Looking Information This press release contains forward-looking statements and forward-looking inf ormation, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and ass umptions and on information currently available to our management. You can ide ntify forward-looking statements by terms such as “may”, “will”, “should ”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “ anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. The forward-looking statements contained in this press rel ease include, but are not limited to, the usefulness of Trogarzo™ and the use of Trogarzo™ in assisting patients in need thereof. Forward-looking statements are based upon a number of assumptions and are subj ect to a number of risks and uncertainties, many of which are beyond Theratech nologies’ control that could cause actual results to differ materially from t hose that are disclosed in or implied by such forward-looking information. The se assumptions include but are not limited to, the following: treating physici ans will adopt the IAS guidelines as it relates to Trogarzo™. These risks and uncertainties include, but are not limited to, the risk that t he treating physicians will not adopt the IAS guidelines as it relates to Trog arzo™. We refer potential investors to the “Risk Factors” section of our Annual Inf ormation Form dated February 6, 2018 available on SEDAR at www.sedar.com for a dditional risks and uncertainties about Theratechnologies and its business. Th e reader is cautioned to consider these and other risks and uncertainties care fully and not to put undue reliance on forward-looking statements. Forward-loo king statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as o f that date. We undertake no obligation to update or revise the information co ntained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law. Media inquiries:ꀊDenis Boucher Vice President, Communications and Corporate Affairs Tel.: (514) 336-7800, ext. 236 1喺AMA, 2018;320(4):379-396 -- ※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 123.204.157.190 ※ 文章網址: https://www.ptt.cc/bbs/Stock/M.1532527456.A.D2D.html

推

s5869157

07/25 22:07, 7年前 , 1^F

07/25 22:07, 1^F

→

isco

07/25 22:11, 7年前 , 2^F

07/25 22:11, 2^F

推

hiller51

07/25 22:28, 7年前 , 3^F

07/25 22:28, 3^F